Leerink Partnrs Estimates Immunocore Q1 Earnings

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for Immunocore in a report released on Wednesday, February 26th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.48) per share for the quarter. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore's FY2025 earnings at ($1.78) EPS.

A number of other equities research analysts also recently weighed in on IMCR. Morgan Stanley reissued an "equal weight" rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $65.64.

Immunocore Stock Performance

Immunocore stock traded up $0.37 during mid-day trading on Friday, reaching $29.25. The company had a trading volume of 249,624 shares, compared to its average volume of 227,774. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -30.79 and a beta of 0.77. The company has a 50 day moving average of $30.09 and a 200-day moving average of $31.76. Immunocore has a 52 week low of $27.69 and a 52 week high of $67.30.

Remove Ads

Institutional Trading of Immunocore

A number of hedge funds and other institutional investors have recently modified their holdings of IMCR. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after acquiring an additional 3,053 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after buying an additional 109,206 shares during the period. Assetmark Inc. raised its position in shares of Immunocore by 6.5% during the 3rd quarter. Assetmark Inc. now owns 30,555 shares of the company's stock valued at $951,000 after acquiring an additional 1,878 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of Immunocore during the 3rd quarter worth about $866,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Immunocore in the 3rd quarter valued at about $406,000. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.